Skip to main content

Robert Friel, Michael Salgaller, Brian Balgley, Marcia Lewis

Robert Friel was elected CEO of PerkinElmer by its board this week. He will assume the position on Feb. 1, succeeding Greg Summe, who has been CEO since 1999.
Friel became president and COO of PerkinElmer in July under a succession plan announced then [See PM 08/02/07]. He will remain president of the company. Friel joined the company in 1999 as CFO.
Summe will remain with the company as executive chairman of the board through the annual shareholder’s meeting in April, 2009.

Calibrant this week said that Michael Salgaller has been appointed its COO, effective immediately. Prior to joining Calibrant, Salgaller was on the investment team at Toucan Capital, a venture firm. Before that he was vice president of clinical and research affairs at Northwest Biotherapeutics. He was an advisor to Calibrant between 2005 and 2006.
Also Brian Balgley was appointed CTO of the company this week. He joined Calibrant in 2003 and led the company’s Gemini drug discovery platform in his previous position as director of proteomics.
In his new position, he will be in charge of advancing the Gemini platform for the differential analysis of proteins from microdissected tissue specimens. He will also lead Calibrant’s drug discovery program.
He directed the University of Maryland’s mass spectrometry core facility before joining Calibrant.

Marcia Lewis has joined Clinical Data as vice president of biomarker development. She had been senior director of oncology programs at Celera where she focused on the identification and validation of diagnostic biomarkers for oncology discovered on the company’s proprietary proteomics platform. She previously held various positions at Bayer Diagnostics.

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.